search icon
      blog search icon

      Viemed Healthcare, Inc. (VMD) stock has seen an incline of 5.16% – Learn why? - Stocks Telegraph

      By Mahrukh Rehan

      Published on

      November 29, 2021

      11:38 AM UTC

      Viemed Healthcare, Inc. (VMD) stock has seen an incline of 5.16% – Learn why? - Stocks Telegraph

      Viemed Healthcare, Inc. (VMD) saw a push of 5.16% in the premarket. However, the last trading session closed at $5.23 with a decrease of 3.15%.

      Third Quarter 2021 Results by VMD– How was the quarter?

      VMD announced third quarter 2021 results on 1st November 2021. According to the report, total net revenues came out to be $29.3 million with $1.5 million in net revenues from contact and vaccination tracking services, as well as product sales associated with the COVID-19 pandemic. Moreover, the Adjusted EBITDA was $7.4 million.

      During the fourth quarter of 2021, the Company anticipates net revenues from its core business of $27.8 million to $28.8 million. While the Company’s COVID-19 response business has slowed this year, it is still pursuing further sales and support revenues, with fourth-quarter 2021 net revenues of $1.5 million to $1.7 million.

      Now what?

      Despite obstacles connected with the Delta variant, VMD is happy to report another record-breaking quarter. The sales team is expecting to get new items to compliment the outstanding service model. Looking ahead, the company is confident in its ability to deliver technology-enabled healthcare in the home setting. This will provide tremendous value and improve patient outcomes.

      Second Published Non-Invasive Ventilation Study – More about it

      On 16th September 2021, VMD announced the Second Published Non-Invasive Ventilation Study. Chronic respiratory failure due to chronic obstructive pulmonary disease has few therapy choices and has a bad prognosis. In patients with COPD-CRF, this study looked at the impact of noninvasive ventilation at home on all-cause mortality, hospitalizations, and emergency department visits. Moreover, individuals with COPD-CRF who got NIVH experienced statistically significant and clinically relevant decreases in hospitalizations. Lastly, the findings imply that receiving NIVH therapy sooner after a CRF diagnosis is linked to a significant decrease in all-cause mortality.

      What’s Next?

      VMD has published evidence supporting the clinical effectiveness of NIVH. The findings back up those of the second research published in December 2020 that utilized different statistical methods. Last but not least, the company will share the findings with physicians, payors, patients, and our industry colleagues in the future.

      More From Stocks telegraph